Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Outcomes of CD20xCD3 bispecific antibody therapy in adult patients with Relapsed/Refractory transformed indolent lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

PSPierre StéphanKCKaran ChohanSASairah Ahmed

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows comparable overall response rates with bispecific antibodies in transformed indolent lymphoma, highlighting a potential treatment option.

Key Points

  • Effective therapy observed with bispecific antibodies in treating high-risk transformed indolent lymphomas.
  • Clinical efficacy demonstrated with overall response rates of 51% in transformed indolent lymphoma after therapy.
  • Multicenter retrospective analysis evaluated safety and efficacy across nine centers and various demographic factors.
  • Findings suggest bispecific antibodies are a promising alternative in managing challenging relapsed/refractory cases.

Cite This Study

Stéphan et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d4f1https://doi.org/10.1182/blood-2025-5521
View Full Paper
Ask AI
Bookmark
Share